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Abstract
Liposomes, a kind of bilayered vesicles formed by self-assembly of phospholipid mol-
ecules in an aqueous medium, are widely used as a vehicle for delivering various thera-
peutic agents due to their high biocompatibility, diverse and high-loading capacity, and 
relative ease for preparation and surface decoration to engender multifunctional features. 
Also, liposomes are a useful carrier for delivering vaccine antigens forming a versatile vac-
cine adjuvant-delivery system (VADS), which can efficiently fulfill both functions of adju-
vancy and delivery when the liposomes are modified with specific functional molecules, 
such as lipoidal immunopotentiators, antigen-presenting cell (APC) targeting ligands, ste-
ric stabilization polymers and charged lipids. In this chapter, liposomes used as a VADS 
are introduced, including the preparation processes for liposomes, the evaluation meth-
ods toward different immunological responses, and also the measures for tracking in vivo 
of the vaccine-carrying liposomes, to provide reader with wide information as a reference 
related to the liposomal VADS.
Keywords: lipid vesicle, bilayer membrane, vaccine adjuvant-delivery system, 
vaccination, immune response, mucosal immunity, humoral immunity, cellular 
immunity, toll-like receptor, pathogen-associated molecular pattern
1. Introduction
Vaccination proves to be the most cost effective and best prophylactic strategy against many 
types of diseases, such as pathogenic infections, cancerous lesions, and even rheumatoid arthri-
tis [1]. The vaccine concept was first introduced in the late eighteenth century by Edward Jenner, 
an English physician and scientist who was the pioneer in development of the world's first 
smallpox vaccine against the fatal virus [1, 2]. All living organisms are continuously exposed to 
substances including those called pathogens, which may invade, reside in, and eventually dam-
age the organisms as their hosts. Fortunately, the invading pathogens can be prevented by the 
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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organisms in several ways: with physical barriers, for example, or with chemicals that repel or 
kill invaders; moreover, in vertebrates (the animals with backbones), mammals and, especially, 
primates (including humans), the pathogens can be further controlled by a more advanced 
protective system called immune system, which is a complex network of organs containing 
different types of cells, such as T cells, B cells and antigen-presenting cells (APCs) [includ-
ing mainly dendritic cells (DCs) and macrophages (MPs)] [2, 3]. Generally, the specific surface 
structures called antigens (Ags) on the pathogens are first recognized by APCs, which are spe-
cialized in uptake and processing the pathogens into fragments to present Ags bound to MHC 
molecules on APC surface as an epitope, which can interact with and stimulate T cells and B 
cells into cytotoxic T lymphocytes (CTLs) and plasma cells, respectively [4]. While the plasma 
cells can secret the Ag-specific antibodies in a substantial amount to neutralize the pathogens 
into harmless non-infectious organisms, CTLs release the cytotoxins, perforin, granzymes and 
granulysin, which work together to trigger a series of the caspase cascade and cause apoptosis 
(programmed cell death) of the pathogen-infected cells, erasing finally the cell-hidden patho-
gens. This process for pathogen defense will also imprint Ag features in immune system setting 
up so-called immune memory, which allows the pathogen-experienced survivors to rapidly 
initiate the immune response toward, and thus erase, the reencountered pathogens bear-
ing the identical Ags [2]. Such ability of immune system obtained after experience to defend 
pathogens defines the concept of immunity, which underlies the fundamental mechanisms for 
the Ag-based vaccines to be developed and employed for prophylaxis of various pathogens, 
including the alien microbes such as viruses, bacteria, fungi, parasites, and even treatment of 
the neoplasma and cancerous lesions in the body [2].
The conventional vaccines are mainly used for prophylaxis of the infectious diseases and are 
usually made of live attenuated or inactivated pathogenic organisms, which, after admin-
istration, can effectively stimulate the body immune systems to set up robust immunity in 
recipients against the related microbes [5]. However, the vaccines based on the live attenuated 
pathogens possess, per se, the potential to cause detrimental infections due to the possible 
mutation occurrence in the engineered organisms and thus may lead to severe outcomes; while 
the vaccines made of inactivated microorganisms may stimulate the rather weak and even 
target-deviated immune response. To enhance the potency of the inactivated microorganism-
based vaccines, the products are often added with alum, which were introduced as a vaccine 
adjuvant in the second decade of last century by Glenny and colleagues [6, 7]. Though alum, 
together with the undefined complex components, can enhance the efficacy of certain vac-
cines, it often causes adverse stimulus reactions and even, gives rise to serious side effects. To 
erase these drawbacks associated with the whole pathogen-based vaccines, researchers have 
recently developed the subunit vaccines, which contain only the essential antigens with the 
well-defined components and, thus, are anticipated to be a safe product without the potential 
risks confronted by the conventional vaccines [8]. Unfortunately, due to lack of other micro-
bial components, which may not only protect the antigens but also be a pathogen-associated 
molecular pattern (PAMP) for mammalian immune systems, the subunit vaccines are usually 
unstable and often induce insufficient immune responses against pathogens [9, 10]. To over-
come these weaknesses of subunit vaccines, numerous types of nanoparticles with composi-
tion mimicking the components of pathogenic organisms have been developed as a vaccine 
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carrier forming the so-called vaccine adjuvant-delivery systems (VADSs), which can protect 
antigens from the environmental damage, deliver ingredients to specific lymphocytes, and 
even enhance, as an adjuvant, the initiation of Ag-specific immune responses [8, 11–14].
Recently, among different types of vaccine carriers, such as emulsions,  poly(lactic-co-glycolic 
acid) (PLGA) particles, silico nanocarriers and virus-like particles (VLPs), liposomes, the 
vesicles made up of lipid bilayers, were first described by Bangham et al. under an electron 
microscope in the early 1960s [15], and have ever since attracted much research interests in the 
development of novel drug delivery system (DDS) or VADS, due to their high biocompatibil-
ity, diverse and high loading capacity, and the ease for preparation and surface decoration to 
engender unique structures bearing the desired functions [16]. In fact, owing to their ability 
to entrap water- and lipid-soluble molecules in their aqueous and lipid phases, respectively, 
liposomes have been used since 1970 as a delivery system in therapeutics for a great variety of 
pharmacologically active agents, including antimicrobial and anticancer therapeutics, vaccines, 
metal detoxification chemicals, DNA/RNA fragments, enzymes and hormones [17]. As confirmed 
by researchers, agent delivery with liposomes can circumvent many of the problems associated 
with direct drug use, for instance, toxicity as a result of indiscriminate drug action, premature 
drug inactivation or excretion, and inability of drugs to reach the target intracellularly. For 
medical application, liposomes have proved able to be safely administered by various routes, 
including the intravenous, intramuscular, subcutaneous, intrathecal, intratracheal, oral, intra-
nasal, and topical (skin and a variety of mucosal tissues) routes, having met with considerable 
success with several liposome-based products, including several vaccines, already licensed for 
clinical use in different countries [18].
Particularly, as a vaccine carrier, liposomes have the intrinsic adjuvant properties, which were 
established as early as 1974 by Gregoriadis and coworkers when strong humoral immune 
responses to liposome-entrapped diphtheria toxoid were observed after injection into mice, 
while, unlike other adjuvants, no granulomas at the site of injection were noticed [19–21]. 
Moreover, there were no hypersensitivity reactions in preimmunized animals when the anti-
gen was entrapped in liposomes and given by intravenous or intra-foot pad injection [20]. 
In the ensuing years, extensive work in this laboratory and elsewhere has shown that lipo-
somal adjuvanticity applies to a wide variety of bacterial, viral, protozoan, tumor, and other 
antigens [19, 22]. Now it is generally accepted that liposome can always function the role of 
adjuvanticity regardless of the type of association of the antigen with liposomes, such as being 
entrapped within the vesicles, attached onto their surface, and even simply mixed together 
[23, 24]. To be efficiently recognized and thus taken up by antigen-presenting cells (APCs), 
liposomes have been explored to be decorated with PAMP molecules and/or the molecules 
as ligands matching the receptors expressed on the surface of the aimed immunocytes, thus 
forming a multifunctional targeting VADS [11, 12, 25–27]. To date, various multifunctional 
liposomes have been developed as a novel VADS targeting APCs to enhance vaccine immuno-
stimulating capacity by utilizing the specific binding affinities between functional molecules 
on the carrier and special features expressed or engendered by the immune cells. For exam-
ple, recently, multifunctional liposomes have been successfully constructed being anchored 
with a toll-like receptor (TLR) ligands, including lipid A for TLR4, CpG-ODN for TLR9, and 
the synthetic molecules with a distal of mannose group for the C-type receptors on APCs, 
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such as dendritic cells (DCs), macrophages (MPs), and even been fabricated into microneedles 
for penetration of skin and mucosa to further enhance delivery efficiency [24]. These kinds 
of multifunctional liposomes as a VADS proved highly effective in both targeting delivery of 
vaccine to APCs and enhancing antigen presentation of APCs to T-cells fulfilling a dual func-
tion of delivery and adjuvancy for vaccines [11, 24, 25, 27, 28].
2. The components and structure of liposomes used for delivery of 
vaccines
Common liposomes are the vesicles made up of one or more concentric lipid bilayers alter-
nating with aqueous spaces [17, 21]. The components of liposomes are mainly amphiphilic 
lipids and include phospholipids such as phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylglycerol (PG), sphingomyelin (SM), or other lipidic amphiphilies such as poly-
sorbate 80 (SPAN80, nonionic surfactants), often supplemented with cholesterol (CHO) and 
other charged lipids such as stearylamine (SA), N[1-(2,3-dioleyloxy) propyl]-N,N,N-triethyl-
ammonium (DOTMA), 1,2-dioleyloxy-3-(trimethylamonium propane) (DOTAP), and 3 (N,N,-
dimethylaminoethane)-carbamyl cholesterol (DMACHO). Figure 1 shows the molecular 
structure of some representative lipids.
At ambient temperature, depending on the nature of the lipids, the liposome bilayers may be in a 
“fluid” or “rigid” state: the fluid state is manifested when liposomes are made with amphiphilic 
lipids that have a gel-liquid crystalline transition temperature (T
c
)— the temperature at which 
the acyl chains melt—below ambient temperature, whereas the rigid state requires liposomes to 
be made of amphiphilic lipids with a T
c
 above ambient temperature [21]. Although liposomes as 
Figure 1. The molecular structure of typical lipids most often used for preparing liposomes. Abbreviations: DOPC, 
1,2-dioleoyl-sn-glycero-3-phosphocholine; DSPS, 1,2-distearoyl-sn-glycero-3-phospho-L-serine; DOTAP, 1,2-dioleyloxy-
3-(trimethylamonium propane); DOTMA, N[1-(2,3-dioleyloxy) propyl]-N,N,N-triethylammonium; CHO, cholesterol; 
DMACHO, 3(N,N,-dimethylaminoethane)-carbamyl cholesterol.
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an agent carrier bear a common weakness of instability, the pegylation (modification with PEG) 
to produce a steric stabilization effect, charging with ionic lipids to engender an electrostatic 
repulsion, and/or lyophilization to form a dry entity renders the liposome-based VADS the sta-
bility completely satisfying the shelf-life requirements for a medicinal product [29].
To date, various types of liposomes have been developed for delivery of drugs or vaccines, 
including unilamellar vesicles, multilamellar vesicles (MLVs), multivesicular liposomes 
(MVLs) (Figure 2) and the liposomes with special structural features, such as cochleates [25, 30], 
bilosomes [31], niosomes [32], the inorganic nanoparticle-cored liposomes such as phospholipid 
bilayer-coated aluminum nanoparticles (PLANs) [28], and the interbilayer-crosslinked multila-
mellar vesicles (ICMVs) [33]. Unilamellar liposomes are a spherical chamber/vesicle, bounded 
by a single bilayer of an amphiphilic lipid or a mixture of such lipids, containing aqueous 
solution inside the chamber. Small unilamellar liposomes/vesicles (SUVs) have sizes up to 100 
nm; large unilamellar liposomes/vesicles (LUVs) may have sizes more than 100 nm up to few 
micrometers (µm), and SUVs or LUVs are often used for specific site-targeting delivery of drugs 
or vaccines. Multilamellar liposomes (MLVs) consist of many Concentric amphiphilic lipid 
bilayers analogous to onion layers, and MLVs may be of variable sizes up to several microm-
eters, while multivesicular liposomes (MVLs) are characterized by their unique structure of 
multiple nonconcentric aqueous chambers surrounded by a network of lipid membranes. Both 
MLVs and MVLs, with multilayers and multi sub-spherules, respectively, can be employed 
for sustained delivery of small chemical drugs or other biological agents, e.g. the MVL-based 
techniques have been developed into a platform of so called DepoFoam for manufacturing the 
extended-release medicinal products, which may release drugs over a desired period of time 
from 1 to 30 days [34]. Notably, DepoFoam has already been used in the FDA-approved com-
mercial products, including DepoCyte® (cytarabine liposome injection), DepoDur (morphine 
Figure 2. Schematic structure of different types of liposomes. Abbreviations: SUV, small unilamellar vesicles; LUV, large 
unilamellar vesicles; MLV, multilamellar vesicles; MVL, multivesicular liposomes.
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sulfate extended-release liposome injection), and EXPAREL® (bupivacaine liposome injectable 
suspension) [18].
3. Preparation and characterization of Ag-loaded liposomes
Since first discovery of liposomes, researchers are always trying to set up different ways for 
preparation of the liposomes that meet the therapeutic demands [35]. Indeed, a variety of 
methods for production of the drug/vaccine delivery liposomes have been developed and are 
now so great that no one laboratory has hands-on experience with all of them [21]. Notably, 
different methods fit different liposomes for entrapping different agents, and, indeed, none of 
them should be regarded as a versatile procedure that can be employed once and for all to pre-
pare any types of liposomes for entrapping drugs [36]. Moreover, certain agents such as the 
small compounds that are neutral and nonionizable can hardly be encapsulated in liposomes 
with a high efficiency by any one of the established processes. Summarily, liposomes used for 
vaccine delivery can be prepared with high encapsulation efficiency (EE) for Ags by exploiting 
two strategies: using unique procedures such as emulsification-evaporation or -lyophiliza-
tion, and constituting special carriers such as charged vesicles. Herein, the method of thin 
film dispersion-extrusion and the method of emulsification-evaporation or -lyophilization are 
introduced because they can be safely used to encapsulate Ags without causing chemical/
mechanical damage to labile biological agents [11, 36–39].
The method of thin film dispersion-extrusion is regarded as the simplest way to prepare the 
liposomes with a control size and can be used for entrapping almost all categories of agents if a 
high EE is not required [15, 36]. This method involves several steps including dissolving lipids 
organic solvents in a round-bottom flask, removing organic solvent by rotation and evaporation 
to make a thin lipid film lining the inside walls of flask, rehydration with an aqueous medium 
of the lipids for dispersion by agitation to engender heterogeneous liposomes, and extrusion 
several times of the coarse liposomes through a series of polycarbonate membranes with size-
defined pores, just obtaining the homogeneous liposomes with a size similar to that of the final 
membrane pores.
3.1. Materials and equipment used for preparation and characterization of Ag-loaded 
liposomes
The main materials include sterile ultrapure water, chloroform, phosphate-buffered saline 
(PBS: 8 g NaCl, 0.2 g KCl, 1.44 g Na
2
HPO
4
, and 0.24 g KH
2
PO
4
 in 1000 mL distilled H
2
O, pH 
of 7.4 adjusted with 0.1 M HCl), the PBS sterilized by autoclaving, soy phosphatidylcholine 
(SPC, molecular weight of 775.04, Avanti Polar Lipids, Inc., Alabaster, Alabama, USA), cho-
lesterol (CHO, molecular weight of 386.65), OVA (ovalbumin) or other Ags, 10 mg/mL of SPC 
stock solution in chloroform, and 10 mg/mL of CHO stock solution in chloroform, and 2 mg/
mL OVA (or other Ags) in PBS containing, or not, 50 mM sucrose, N
2
 gas tank, liquid nitrogen, 
Triton-X100,: Sephadex G-50 (medium) gel (Pharmacia Company), Coomassie Brilliant blue 
G-250 (Sigma-Aldrich), Bradford reagent: Dissolve 50 mg of Coomassie Brilliant Blue G-250 
in 50 mL ethanol, add 100 mL 85% (w/v) phosphoric acid (H
3
PO
4
). For charged or stealth 
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liposomes to be used for carrying Ags, 1,2-dioleyloxy-3-(trimethylammonium propane) 
(DOTAP, a cationic lipid), soy phosphatidylserine (SPS, an anionic lipid), and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)
2000
 (DSPE-PEG
2000
) may 
be included.
The equipment and apparatus include 50-mL round-bottom flask, vortex mixer, 10-ml LIPEX® 
Extruders (Transferra Nanosciences Inc., Burnaby, B.C. Canada), membranes with the pore 
sizes of 400, 200, 100, and 50nm (Avestin, Ottawa, ON, Canada), a rotary evaporator, a probe 
or water bath sonicator with working frequency of 20 kHz, a vacuum desiccator, and a freeze-
dryer, Malvern Zetasizer Nano ZS90 (Malvern instruments Ltd., Malvern, Worcestershire, 
UK), A FEI Tecnai G2 Spirit—transmission electron microscope (FEI Company, Hillsboro, 
Oregon, USA) and Vitrobot™ Cryo-TEM sample preparation instrument, a Micro CS150NX 
Ultracentrifuge (Hitachi, Japan) or other equivalent, 8453 UV-Vis spectrophotometer (Agilent 
Technologies, Inc., Santa Clara, California, USA) or other equivalent.
3.2. Preparation of Ag-loaded liposomes by thin film dispersion-extrusion method
1. To prepare 2 mL SPC/CHO liposomes (1:1, molar ratio) with lipid concentration of 10 mg/
mL, 1330 µL of 10 mg/mL SPC stock solution and 670 µL of 10 mg/mL cholesterol stock 
solution are mixed in a 50-mL round-bottom flask in a chemical hood, and then organic 
solvent is removed on a rotary evaporator linked to a recycling water vacuum pump with 
flask dipped in a water bath at 35–40°C under reduced pressure. (For charged liposomes 
used for vaccine delivery, the lipid components can be replaced with SPC/CHO/DOTAP 
(4.5:4.5:1, molar ratio), or SPC/CHO/SPS (4.5:4.5:1, molar ratio); for stealth liposomes, the 
lipid components may be SPC/CHO/DSPE-PEG
2000
 (9.5:9.5:1, molar ratio), or other combi-
nations depending on the carriers to be used.)
2. The opening of the lipid film-adhering flask is covered with a piece of stretched parafilm 
to prevent the entry of dusts or contaminants and poke few small holes in the parafilm by 
a needle, and then the lipid film-adhering flask is put in a vacuum desiccator overnight to 
remove organic solvent residue.
3. Then 2 mL of PBS containing 2 mg/mL OVA (model Ag) is added to the dry lipid film-
containing flask, which is vortexed repeatedly for 10 s on maximum speed until the lipid 
materials are all suspended in the solution.
4. The sample is sonicated for 5 min at the power of <100 W to disperse all visible precipitates 
and obtain milky crude liposome sample of mostly MLVs.
5. Repeatedly, the liposome sample is extruded with high pressure N
2
 gas to pass through 
the 400 nm-pore polycarbonate membranes 11 times using the Extruder, which is then 
re-equipped with polycarbonate membranes of the pore size, in sequence, of 200, 100, and 
50 nm, each followed by the due 11-cycle extrusion, and, consequently, resulting in the 
liposomes with a size of about 420, 220, 120, and 60 nm after each of the 11-cycle extrusion 
through the corresponding membranes.
6. The liposome preparation is stored in a vial filled with N
2
 gas at 4°C in the dark.
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3.3. Preparation of Ag-loaded liposomes by emulsification-evaporation/lyophilization 
method
1. To prepare 2 mL of SPC/CHO liposomes (1:1, molar ratio) with lipid concentration of 10 
mg/mL, 1330 µL of 10 mg/mL SPC stock solution and 670 µL of 10 mg/mL cholesterol stock 
solution are mixed in a 20-mL ample, which contains 4 mL cyclohexane resulting in 6 mL 
of lipids dissolved in cyclohexane/chloroform (3:1, v/v) to be used as oil phase (O).
2. And 6 mL of O is mixed with 2 mL of 2 mg/mL OVA PBS with (for emulsification-lyophi-
lization method) or without (for emulsification-evaporation method) 50 mM sucrose as 
water phase (W), and then using an ice/water bath to control the temperature under 30°C, 
the mixture is emulsified with a sonicator with work frequency of 20 kHz at the power of 
50 W to make a W/O type emulsion.
3. By emulsification-evaporation method, the W/O emulsion is evaporated at 35–40°C under a 
slightly reduced pressure to remove slowly all the organic solvents, and then sample is sup-
plemented with appropriate amount of PBS to obtain finally 2 mL of liposome preparations; 
otherwise, by emulsification-lyophilization method, the following steps should be completed.
4. The obtained 8 mL of W/O emulsions are mixed with 12 mL of PBS containing 50 mM 
sucrose and mildly emulsified using homomixer at 5000 rpm for 1 min to form a W1/O/
W2 double emulsion, which is quickly subdivided and filled into 5-mL freeze-drying vials 
with a fill volume of 1 mL per vial.
5. The emulsion-containing vials are immediately put into an ultra-low temperature refrig-
erator and frozen at −85°C for 4 h, and then transferred into a freeze-dryer and lyophilized 
with a program as follows: primary drying at −45 and −20°C for 2 h periods, respectively; 
and secondary drying at 20°C for 4 h.
6. After lyophilization, the vials are immediately filled with nitrogen gas, sealed, and stored 
at 4°C in the dark.
7. For use, an appropriate amount (0.1–1 mL) of water is added into the dry powder-contain-
ing vial, resulting in the Ag-loaded liposomes with lipid concentration of 10–1 mg/mL.
3.4. Characterization of the Ag-loaded liposomes
3.4.1. Test of size and zeta potential
The Ag-loaded liposomes may be characterized in size (mean diameter), zeta potential (ζ), 
morphology, and structure.
The size (mean diameter) and surface charge (zeta potential, ζ) of the multifunctional 
liposomes with or without antigen are tested using a Malvern Zetasizer ZS90 (Malvern, 
Worcestershire, UK) referring to the user manual.
Test of liposome size by DLS (dynamic light scattering) is usually performed using samples 
with lipid concentration of 1 mg/mL. Thus, 0.2 mL of the prepared liposomes is diluted with 
1.8 mL of PBS (with or without sucrose) in a polyacrylate or quartz cuvette and placed in 
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Zetasizer ZS90, and the particle size is determined by photon correlation spectroscopy (PCS) 
at 25°C at an angel of 90°, to give the intensity, number or volume mode, which can be used to 
evaluate the particle size distribution profile which is automatically summarized as parameter 
of polydispersity index (PDI), while the size is often presented with the average one plus PDI.
For ζ test by electrophoretic light scattering (ELS), 0.7–1 mL of the diluted sample is pipetted into 
the polyacrylate or quartz cuvette, which is then carefully inserted with the “Dip” cell bearing 
electrode pair, placed in Zetasizer ZS90 and determined by PCS at 25°C at an angel of 90°.
3.4.2. Cryo-TEM of multifunctional liposomes
The electron microscope is a type of microscope that uses a beam of electrons to create an image 
of the specimen and has up-to-date the greatest resolving power, allowing it to see nano-sized 
objects in fine detail [40]. It is large, expensive pieces of equipment, generally standing alone in 
a small, specially designed room and requiring trained personnel for operation. Recently, the 
cryo-transmission electron microscopy (cryo-TEM) has gained great development and allows 
the observation of specimens that have not been stained or fixed in any way, just showing them 
in their native environment at, notably, even near-atomic resolution [40]. Since early 1990s, the 
cryo-TEM has been more and more employed by researchers to observe the morphology and 
structure of the agent-loaded liposomes. Since the liposome surface is always hydrophilic, the 
hydrophobic carbon grid that used to carry liposomes should be first converted to hydrophilic 
nature by glow discharge. For cryo-TEM, the sample-holding grid is usually freezed in liquid 
nitrogen at −196°C for 10 min and transferred to a cryo-holder, which is maintained at ultralow 
temperature using a liquid nitrogen storage box, and then inserted in the microscope for imaging 
in the ultralow temperature [39].
The following protocol may apply to observation of the Ag-loaded liposomes by cryo-TEM [39].
1.  Using a pipette, 3 µL of the sample is applied to an EM grid that has been converted to 
hydrophilic nature by glow discharge.
2. After being blotted with filter paper to remove excess sample, the grid is plunged into 
liquid nitrogen at −196°C for 10 min, and then transferred to a cryo-holder, which can be 
maintained at ultralow temperature using a liquid nitrogen storage box.
3. Then the cryo-holder is inserted into the EM column that is maintained at liquid nitrogen 
temperature (77 K), and the liposome sample is imaged at the ultralow temperature.
3.4.3. Determination of EE of the Ag-loaded liposomes
The EE of the Ag-loaded liposomes may be estimated by the following Eq. (1).
  EE  ( % )  =  Total Ag − Free Ag  ______________
Total Ag
  × 100% (1)
Free Ag may be separated from Ag-associated liposomes by ultracentrifugation and quantita-
tively determined with the classical Bradford protein assay method [41]. For free Ag separation, 
the liposome sample is centrifuged at 100,000 × g in an ultracentrifuge for 1 h, and then after 
collection of the free Ag-containing supernatant, the liposomal pellet is suspended with PBS for 
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washing and centrifuged again. The supernatants are mixed together to adjust protein concen-
tration at a range of 0.1–25 µg/mL, and Ag quantification may be carried out by the following 
procedure.
1. Five standard solutions (1 mL each) containing 0, 0.1, 0.4, 1.6, 6.4, and 25.6 µg/mL BSA are 
prepared.
2. And 800 µL of each standard and sample solution (containing for < 25 µg/mL protein) is 
pipetted into a clean, dry test tube. Protein solutions are normally assayed in duplicate or 
triplicate.
3. Then 200 µL of Bradford dye reagent concentrate is added to each tube followed by vortex 
for mixing.
4. The tubes are incubated at room temperature for at least 5 min. Absorbance will increase 
and changed nonlineally over time, and samples should be incubated at room temperature 
for not more than 1 h.
5. The standard and sample solutions are transferred into cuvette and measured immediately 
of the absorbance at 595 nm.
6. The standard curve is obtained and used to quantify free Ags.
3.4.4. Assay of Ag integrity in liposomes using SDS-PAGE
During incorporation in liposomes, the Ag may be damaged due to its possible confronta-
tion of the organic solvents and intense mechanic sonication and therefore should be scru-
tinized of the integrity. Usually, sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) is used to test the integrity of the Ags entrapped in liposomes that are freshly 
prepared or have been stored in certain conditions for some time for evaluating the stability 
of the products [42]. The protocol of SDS-PAGE test of the Ags loaded in vaccine carriers has 
been described in detail in an open access book chapter and is suggested as a reference for 
investigators [39].
4. In vitro and in vivo evaluation of the Ag-loaded liposomes
4.1. Materials and equipment used for evaluation of the Ag-loaded liposomes
For assay of the immunity elicited in vitro and in vivo by vaccination with Ag-loaded lipo-
somes, the following materials should be at hand: HyClone Roswell Park Memorial Institute 
(RPMI) 1640 medium and fetal calf serum (FCS) by Thermo Fisher Scientific (Waltham, 
MA, USA), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)) and TMB 
(3,3,5- tetramethylbenzidine) by Sigma-Aldrich (St. Louis, MO, USA); LysoTracker-red and 
(4’,6-diamidino-2-phenylindole) DAPI (Thermo Fisher Scientific Inc., Waltham, MA, USA) for 
label cellular organelles of lysosome and nucleus, respectively; and the biological agents for 
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assay of immunoglobulins and cytokines, such as IFN-γ and IL-4 assay kits; goat anti-mouse 
IgG-horse radish peroxidase (HRP), IgG1-HRP, IgG2a-HRP (or IgG2c, if C57BL/6 mice are 
used) and IgA-HRP with sales package of 200 µg per 0.5 mL, PE-conjugated anti-mouse CD8+ 
mAb (monoclonal antibody) and FITC-conjugated anti-mouse CD4+ mAb and other fluores-
cently labeled immunological agents for assay by eBioscience (San Diego, USA), BioLedend 
(San Diego, USA), or Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA).
For assay of the immunity elicited in vitro and in vivo by vaccination with Ag-loaded lipo-
somes, the following equipment will be used: a microplate reader (µQuantTM, BioTek 
Instruments, Inc., Vermont, USA), a fluorescent microscope (Olympus IX83, Japan) or other 
equivalent, a laser scanning confocal microscope (LSCM) (Leica TCS SP5, Wetzlar, Germany) 
or other equivalent, flow cytometry (BD FACSVerse™, San Jose, CA, USA) or other equiva-
lent, and the flow cytometry data analysis software of FlowJo (Tree Star, Ashland, OR, USA).
4.2. In vitro evaluation of vaccine adjuvancy and delivery ability of the Ag-loaded 
liposomes through cellular experiments
It is believed that after antigen uptake, APCs with normal functions will evolve from immature, 
antigen-capturing cells to mature, antigen-presenting and T cell-priming cells, and meanwhile 
able to convert antigens into immunogen epitope and express molecules such as cytokines, che-
mokines, costimulatory molecules and proteases to initiate an immune response. Thus, the abil-
ity of delivery of Ag to APCs is one of the main functions designed to the liposomal carriers and 
is usually evaluated through assaying enhancement of cellular uptake of the fluorescent agent/
Ag-loaded liposomes using mouse bone marrow-derived macrophages (BMMPs) and dendritic 
cells (BMDCs), both of which are confirmed to be ideal APCs to evaluate vaccine adjuvancy and 
delivery efficiencies and can be generated from bone marrow precursors as follows [43, 44].
1. The femur bones are first isolated from the euthanized mouse, and then immersed in 75% 
ethanol for 2 min for disinfection
2. After rinsing thrice with sterile PBS, both ends of femur bones are removed, and bone 
marrow is flushed out with ice-cold PBS using a hypodermic needle attached to a syringe.
3. The leukocytes obtained are washed thrice with PBS and then transferred into bacteriologi-
cal petri dishes and cultured in 10 mL of complete RPMI containing 10% heat-inactivated 
FBS and in the presence of 50 µM 2-mercaptomethanol and 20 ng/mL GM-CSF for 3 days 
in a cell culture chamber.
4. On days 4 and 6, the culture medium is replaced with the fresh one containing identical 
ingredients.
5. On day 8, the nonadherent cells in culture medium are used as BMDCs.
Similarly, BMMPs can be obtained using the above protocol with a little modification in Step 
4 by replacing GM-CSF with M-CSF, and in Step 5, and, notably, the adherent cells instead of 
nonadherent cells in culture medium are collected as BMMPs.
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The cellular uptake of the fluorescent agent/Ag-loaded liposomes may be assayed by follow-
ing processes.
1. APCs (BMDCs or BMMPs) are seeded in a 24-well plate with 1 mL of 105 cells/well and 
incubated in a cell culture chamber with 5% CO
2
 at 37°C for 24 h.
2. Then each cell well is supplemented with 50 µL of calcein (1 mM)/Ag-loaded liposomes, 
mixed homogeneously, and incubated continuously in a cell culture chamber at 37°C for 
various times.
3. After the incubation and removal of the unassociated agents or liposomes through cen-
trifuge at 800 g for 5 min and washing thrice with PBS, the cocultured cells (105 cells/mL) 
are analyzed by flow cytometry for uptake of liposomes with data analysis using FlowJo 
software; otherwise, a fraction of the cells is imaged using a fluorescent microscope; or to 
observe the intracellular localization of the agents delivered by liposomes in APCs, the fol-
lowing steps are carried out
4. The cocultured cells are isolated and incubated for 30 min in pre-warmed media (37°C) 
containing 50 nm LysoTracker-red and DAPI to identify lysosome and nuclei, respectively.
5. After washing thrice, the APCs are observed in a LSCM, and the dissociation of green dots 
(calcein-liposomes) from red dots, with blue nuclei for cell localization, is considered as the 
hallmark of lysosome escape by agents delivered by liposomes.
APC activation and maturation induced by the Ag-loaded liposomes can be evaluated by 
assay of the immunological cytokines and the surface biomarkers secreted or expressed by the 
APCs in the activated states. The secretion of cytokines, such as tumor necrosis factor (TNF), 
various interleukins (ILs), IFN-γ and even nitric oxide (NO), is usually enhanced or altered 
to different degrees by the activated APCs for induction of the subsequent specific immune 
responses, whereas CD40, CD80, and CD86 are known to be expressed at an enhanced level 
on the activated APCs and involved in, through binding receptors on T cell surface, providing 
costimulatory signals necessary for T cell activation and survival, and therefore may be used 
as markers for evaluating APC activation state. The levels of CDs on surfaces of the activated 
APCs may be assayed by several steps as follows:
1. The cells seeded in a 24-well plate with 1 mL of 106 cells per well are supplemented with 
50 µL of soluble Ags (as a control), Ag-loaded liposomes at the dose of 20 µg Ag for up to 
30 h for stimulation.
2. After stimulation, the cells are labeled with different color fluorochrome-conjugated Abs 
against surface biomarkers, such as CD40, CD80, and CD86, at 37°C for 30 min.
3. The cells are quantitatively assayed of the CD levels by flow cytometry.
The levels of cytokines, such as TNF, various ILs and IFN-γ, secreted in culture medium by 
the activated APCs are first separated in the supernatants by centrifugation and quantified 
with enzyme-linked immunosorbent assay (ELISA) kits according to product performance 
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guidance, while the level of secreted NO in cell culture supernatants is usually measured by 
colorimetric assay with Griess reagents, which react with nitrite forming a colorimetric com-
pound which in turn reflects NO amount in samples [45].
The antigen presentation profile of the liposome-activated APC with MHC-I or -II is usually 
determined by measuring APC-primed CD8+ and CD4+ T cell proliferation using Ag-specific 
T cells as the following protocol.
1. To obtain Ag-specific T cells, C57BL/6 mice are immunized subcutaneously in the scruff of 
the neck with daily dose of 100 µg OVA plus 10 µg Poly (I:C) at injection volume of 100 µL 
[46], and mice are repeatedly immunized at the same site, at approximately 24-h intervals 
for 4 consecutive days.
2. Seven days after the first immunization, Ag-specific CD8+ T cells are negatively selected 
from the spleen of Ag/Poly (I:C)-immunized mice by magnetic bead adsorption using 
MagniSort® isolation kit.
3. The isolated CD8+ T cells are prelabeled with CFSE (1 µM final concentration for 106 cells) 
at 37°C for 5 min, and then cocultured with the Ag-loaded APCs that are generated by 
stimulation with free Ag (used as a control) or Ag-loaded liposomes at the ratio of T cell 
to APC of 10:1, at 37°C for 48 h [47, 48]. To determine MHC II antigen presentation ability 
of APCs, CD8-depleted splenocytes are prelabeled with CFSE and cocultured with OVA-
loaded APCs at the ratio of T cells to APCs at 10:1 at 37°C for 48 h.
4. The proliferation of CD8+ T cells and CD4+ T cells, which, respectively, reflected the MHC I 
and MHC II antigen presentation by APCs, is determined by measuring the fraction of live 
cells with decreased CFSE intensity (CFSElow cells) using flow cytometry.
4.3. In vivo evaluation of vaccine adjuvancy-delivery ability of the Ag-loaded liposomes 
through vaccination experiments
4.3.1. Animal vaccination with the Ag-loaded liposomes
The experimental animals, such as mice, rats, rabbits and dogs, can be used as a vaccination 
model for Ag-loaded liposomes. Though rats, rabbits and dogs can be used for vaccination of 
Ag-loaded liposomes, mice are a preferred model due to their relatively low price, small body 
saving liposome samples, and, most importantly, their immune system bearing much-known 
backgrounds [49]. The vaccination routes are diverse and can be summarized into two ways: 
injection and noninjection, and the former includes intradermal, intramuscular, intramucosa and 
intravenous injection, while the later includes intraoral cavity, intravaginal, oral-uptake adminis-
tration. Notably, intramucosa is a newly developed pathway and has been investigated only for 
vaccination of the microneedle vaccines, which have also been invented only recently but devel-
oped rapidly to show big advantages over the conventional liquid vaccines in the several aspects 
including the administration convenience, dosage saving, and, especially, efficient delivery of 
Ags [12–14, 24, 26, 27, 50–52]. The Ag dose given to mice in the formulation of liposomes is often 
in the range of 0.5–20 µg for injection, but of 5–100 µg for intracavity administration.
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4.3.2. Sample collection
Collection of samples, including blood, secreted fluids in reproductive ducts and respira-
tory tracts, and even contents in digestive lumen and cavities from mice vaccinated with the 
Ag-loaded liposomes is necessary to obtain the data on a wide range of parameters, such as 
immunoglobulins, interferons, interleukins and cytokines, to evaluate humoral and cellular 
immune responses to vaccines. The sample collection from the vaccinated mice is suggested 
to be carried out 2–4 weeks after vaccination, when the immune responses are thought to be 
in a prime period. The protocols for collection of various samples, including blood, saliva, 
pulmonary, respiratory, vaginal and intestinal secretions, are described in detail in an open 
access book chapter recently published by Springer and suggested here as a reference and 
guide to performing the corresponding experiments [26].
4.3.3. Isolation of splenocytes from mouse spleen
Proliferation profile of the immunocytes from treated mice reflects the level of the immune 
responses to a liposomal vaccine and can be sketched using the different types of immuno-
cytes and their fractions in lymphoid tissues, such as spleen, lymph nodes (LNs) and thymus 
to show the pathways along which the immune responses elicited by a liposomal vaccine 
have progressed and developed. Therefore, isolation and assay of immune cells from lym-
phoid tissues are often carried out as one of the fundamental mechanisms underlying the 
immunological efficacy of certain types of vaccines. Usually, organ, tissue, or cell isolation 
should be performed with aseptic manipulation in a sterile cabinet or under a sterile condi-
tion to avoid contamination for keeping cells alive.
Isolation of mouse splenocytes from spleen is described as follows:
1. The spleen from the abdomen-anatomically opened mouse is isolated using a small pair 
of hemostatic forceps, and transferred into the cell strainer (200-mesh with pore size of 70 
µm) in the Petri dish containing 2 mL sterile PBS.
2. The spleen is ground slightly with the plunger of a 2-mL syringe by grinding circular 
movements to release the splenocytes into the Petri dish through passing the strainer.
3. Periodically, liquid from outside the strainer is pipetted to wash out the cells from within 
the strainer. Continuously, the spleen is slightly mashed until all that remains is the white 
connective tissue of the outer membrane.
4. The splenocyte suspensions are collected, filtered through the strainer twice if necessary, 
and transferred into a 5-mL tube, and the Petri dish may be washed out with 1-mL PBS 
twice to maximize the cell recovery.
5. The splenocyte suspensions are centrifuged at 800 × g for 5 min at room temperature and 
discard the supernatant by decant.
6. The splenocyte pellet is fully resuspended in 1-mL red blood cell lysing solution (containing 
155-mM NH
4
Cl, 12-mM NaHCO
3
, 0.1-mM EDTA) and left for just 2 min at room tempera-
ture to lyse the red cells.
Liposomes142
7. The suspensions are diluted immediately with 4 mL PBS, and centrifuged at 800 × g for 5 
min to discard the supernatant, and the pellet is resuspended in the cells completely in a 
full volume of PBS and washed twice with PBS following each centrifuge.
8. Finally, the cells are suspended in a proper medium (e.g. RPMI-1640) to a final known 
volume, and live cells are counted using a hemacytometer under a light microscope after 
Trypan blue staining.
Mouse lymphoid node immunocytes are isolated using the protocol as follows [28].
1. The anesthetized or euthanized mouse is put on its side to localize the region of the super-
ficial (e.g., inguinal or brachial lymphoid node) to be harvested.
2. After disinfection with chlorhexidine or other disinfectants of the skin region that covers 
the lymph node, the skin is opened with a tiny incision (about 5 mM) with scissors.
3. The incision is stretched with two forceps to find the lymph node, which may appear gray-
ish or darker than the surrounding fat.
4. The fascia (thin membrane covering the fat and tissue) on top of the lymph node is pinched 
with one pair of forceps and pulled lightly without breaking the surrounding tissue, then 
the lymph node is clamped with the second forceps from the underneath and is removed 
with the first forceps by breaking the fascia.
5. The lymph node is place in a 5- or 10-mL tube containing PBS and should immediately sink 
to the bottom of the tube, validating that a lymph node but not fat tissue has been extracted.
The obtained lymph nodes can be further subjected to lymphocytes isolation or histological 
section for immunological assay.
The immune cell proliferation can be tested by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-
yltetrazolium bromide) method.
1.  MTT solution is prepared by dissolving 50 mg MTT in 10 PBS followed by filtering through 
0.2-µm membranes for sterilization.
2. A cell suspension is adjusted to contain 0.1–1.0 × 106 cells/mL in a medium and is seeded 
with 100 µL of cells per well in a 96-well plate, or with 500 µL of cells per well in a 24-well 
plate is seeded, with or without the compound to be tested.
3. The seeded cells are cultured for 24–96 h at 37°C and 5% CO
2
 in a humidified incubator, 
and then 10 µL of 5 mg/mL MTT in PBS is added to each well of a 96-well plate, or 50 µL 
to each well of a 24-well plate.
4. The plate is incubated at 37°C and 5% CO
2
 for 3–4 h (resulting in purple precipitates within cells, 
and the intracellular precipitates can be more precisely visualized under a light microscope).
5. The culture medium is carefully removed using a pipette (after centrifuge at 800 g for 5 
min for nonadhesive cells), and Dimethyl sulfoxide (DMSO) is added at the amount of 
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100 µL per well for a 96-well plate, or 500 µL per well for a 24-well plate, which is incubated 
at room temperature for 2 h in the dark to fully dissolve the intracellular precipitates. 
(Note: Longer incubations with DMSO in the wells may result in precipitate or turbidity 
that can increase background. If precipitate is observed, warm the plate at 37°C for 10–20 
min and agitate to dissolve the precipitate.)
6. The plate optical absorbance is finally read at a wavelength of 560 nm with a reference 
wavelength of 650 nm.
4.3.4. Humoral immunity assays
The antigen-specific antibodies, such as IgA, IgG, and IgG2a (or IgG2c in case of samples 
from C57BL/6 mice), produced in mice vaccinated with Ag-loaded liposomes can be assayed 
using the method of enzyme-linked immunosorbent assay (ELISA) in a microplate reader 
(µQuantTM, BioTek Instruments, Inc., Vermont, USA) [25, 28]. There are five types of ELISA, 
including indirect ELISA, direct ELISA, sandwich ELISA, competitive ELISA and ELISPOT, 
and only a few differences exist amid these ELISA protocols, with the main ELISA principle 
and lots of procedures being the same. The level of anti-Ag antibody is often determined by 
the conventional indirect enzyme-linked immunosorbent assay (ELISA) protocol as follows:
1. A 96-well microtiter plate is coated per well with 100 µL of Ag (capture protein) (1 µg/mL) 
in carbonate buffer (15 mM Na
2
CO
3
, 35 mM NaHCO
3
, pH 9.6) and sealed and incubated 
at 4°C overnight.
2. Each well of the plate is aspirated with pipette to discard the contents and washed three 
times with 300 µL of PBS containing 0.05% v/v Tween-20 (PBST). After the last wash, the 
plate is inverted and blotted against clean paper towels to remove any remaining PBST.
3. Each well is blocked by adding 200 µL of PBSTO (PBST containing 1 mg/mL OVA, or 
protein other than the Ag in liposomes) and then covered and incubated at 37°C for 1 h to 
prevent the nonspecific binding sites in the coated wells and then blotted on paper towels 
after discarding of water.
4. Thereafter, 100 µL of samples, which have been collected from mice and diluted appro-
priately with PBSTO, is added to each well of the plate, sealed, incubated at 37°C for 1 h.
5. After being washed thrice with 200 µL of PBST and blotted on paper towels after last wash, 
each well is added with 100 µL of the HRP (horseradish peroxidase)-conjugated secondary 
antibodies that have been diluted with appropriate amount of PBSTO (1:2500) and sealed 
for incubation at 37°C for 1 h.
6. After being washed with 300 µL of PBST for five times and blotted on paper towels after 
last wash, each well is supplemented with 100 µL of the freshly prepared TMB (3, 3′, 5, 
5′-Tetramethylbenzidine) substrate solution (containing 1 mM TMB, 3 mM H
2
O
2
 and 0.2 
mM Tetrabutylammonium Borohydride (TBABH)) and incubated at room temperature in 
the dark for 20 min for color development [25, 53].
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7. And 20 min later, each well is added with 100 µL of 1 M H
2
SO
4
 solution to terminate the 
color development and then immediately determine the optical absorbance at 450 nm, 
with a reference wavelength at 570 nm, using an automated microplate reader (µQuantTM 
microplate spectrophotometer, BioTekInstruments, Inc., Winooski, Vermont, USA).
Notably, in above Step 6, TMB substrate solutions should be freshly prepared and used in 
less than 10 min, because they are chromogenic reagents for peroxidase to develop an intense 
blue color that can be read directly (at 650 nm), or a deep yellow color (read at 450 nm) after 
stopping with an acid solution.
And 1 mM TMB substrate solution (containing 1 mM TMB, 3 mM H
2
O
2
) can be freshly pre-
pared as follows:
1. Preparation of Solution A: Potassium citrate buffer solution (CBS) is prepared by dissolv-
ing 2.15 g citric acid in 40 mL H
2
O, which is then adjusted of pH 4 with 1 M KOH and 
diluted with H
2
O to 50 mL, and then 50 mL of CBS is then mixed with 15 µL of fresh H
2
O
2
 
(30%), resulting in Solution A.
2. Preparation of Solution B: A total of 10.8 mg TBABH (Tetrabutylammonium Borohydride) 
is dissolved in 5 mL dimethyl acetylamide (DMA), into which 50.3 mg TMB is then added 
and dissolved by vertex, resulting in Solution B.
3. Preparation of 1 mM TMB substrate solution: Just before use, 8 mL of Solution A is com-
pletely mixed with 200 µL of Solution B, resulting in 8.2 mL 1 mM TMB substrate solution.
4.3.5. In vivo tracking of the Ag-loaded liposomes after vaccination
To track in vivo vaccines delivered by liposomes, both ex-vivo approaches and in-vivo imag-
ing techniques can be used, including ex-vivo biodistribution, autoradiography, MRI, optical 
imaging, PET and single-photon emission computed tomography (SPECT), all of which have 
their specific advantages and limitations. Consequently, selection of the tracking method 
should be based on the distinct features of the nanocarriers as well as the specific aims of the 
experiments [54, 55]. Here, this section introduces a simple fluorescent method that is con-
veniently applied for tracking vaccine delivery system. For this, the fluorescent agents, such 
as calcein and sulforhodamine B (SRB), are efficiently entrapped due to their water-soluble 
properties as a label in the Ag-loaded liposomes, enabling both ex-vivo and in-vivo imaging 
approaches to be used for tracking the vaccines.
For in-vivo imaging, usually, 0.5, 1, 2, 4, and 8 h after administration of the fluorescent agent/
Ag-loaded liposomes via intradermal, intramuscular, intra-mucosal or any other feasible 
route, mouse is imaged using animal in vivo imaging systems; otherwise, mouse is exposed, 
by anesthetic and anatomic operation, of mucosa, lymph nodes (LNs), or other region wherein 
vaccines are expected to be delivered by liposomes, to lights with the wavelength matching 
fluorescent agent entrapped in liposomes for automatic imaging using a camera or a smart 
phone with lens [24].
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For ex-vivo imaging and assay, at 0.5, 1, 2, 4, and 8 h after vaccination mice with fluorescent 
liposomes, the organs, such as spleen, liver, kidney, heart, lung and even brain, and main 
draining LNs that collect the fluids from the administration site and nearby regions are dis-
sected from the vaccinated mice for further histological section assay. To observe distribution 
of fluorescent liposomes, the freshly harvested organs and draining LNs should be immedi-
ately embedded in the optimum cutting temperature (OCT) compound for cryosection and 
observation under a fluorescence microscope (IX83, Olympus, Japan). The procedure for cryo-
sectioning is relatively simple and can be performed rather quickly, using the material includ-
ing necessarily frozen embedding media of OCT, empty slide box, dry ice, cryostat, which 
is essentially a microtome inside a freezer, disposable blades, specimen mount, slides, and 
optionally poly-L-Lysine, gelatine, and agarose.
1. The fresh, unfixed tissue sample, up to 2.0 cm in diameter, is frozen in OCT in a suitable 
tissue mold in liquid nitrogen or at −80°C in an ultralow temperature refrigerator. Certain 
soft tissues, such as brain, are optimally frozen in M-1 medium at −3°C.
2. The tissue-embedded OCT is fixed and frozen onto the specialized metal grids fitting onto 
the cryostat.
3. Sections of 5–15 µm thickness are cut in the cryostat at −20°C. If necessary, the temperature 
of the cutting chamber may be adjusted up or down of ±5°C, depending on the tissue un-
der study. A camel hair brush is useful to help guide the emerging section over the knife 
blade.
4. Within 1 min of cutting a tissue section, the section is transferred to a room temperature 
microscope slide by touching the slide to the tissue, avoiding freeze-drying of the tissue. 
Poly-L-lysine-coated or silanized slides improve the adherence of the section. And to eval-
uate tissue preservation and orientation, the first slide of each set may be stained with 
toluidine blue (1–2% w/v in H
2
O), hematoxylin, and eosin, or any aqueous stain.
5. The sample-loaded slide is immediately immersed into an appropriate fixative, such as in 
precooled acetone (−20°C) for 10 min, which is then poured off and allowed to evaporate 
from the tissue sections for less than 20 min at room temperature, and then rinsed thrice 
with plentiful PBS.
6. The slide is stained of nucleus with DAPI for immediate observation. Otherwise, the slide 
may be covered with a layer of OCT to prevent freeze-drying and stored the rest of the sam-
ple at −70°C for further assay. For long-term storage, a moistened tissue should be added 
to the container with the block to prevent desiccation (particularly in a frost-free freezer).
In addition, the draining LN immunocytes that had taken up the liposomes can be sorted out 
by distinct fluorescent Ab staining using flow cytometry assay as follows.
1. The harvested draining LNs are gently mashed and filtered through a strainer with 70-µm 
mesh to isolate immune cells.
2. The resulting cells are stained at 4°C for 2 h with different fluorescent dye-conjugated Abs 
against CD11b, CD11c, F4/80, and CD169.
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3. The stained cells are analyzed by flow cytometry to estimate the dLN cells that had en-
gulfed either nanocarriers and their fractions based on fluorescence of liposomes and 
cells, which can be distinguished according to expressions of CD11c+F4/80− by DCs, 
CD11b+F4/80−CD169+ by subcapsular sinus macrophages (SSMs), CD11b+F4/80+CD169+ by 
medullary sinus macrophages (MSMs), and CD11b+F4/80+CD169− by medullary cord mac-
rophages (MCMs) [24].
4.3.6. In vivo assay of activation of lymphocytes and generation of memory lymphocytes
The immune induction effects by vaccines on lymphocyte activation, memory lymphocyte 
differentiation, and Ag-specific CD8+ T cell production, are also often evaluated by flow 
cytometry.
1. Three weeks after final immunization with the Ag-loaded liposomes or the control formu-
lations, the treated mice are anesthetized with chloral hydrate and aseptically isolate the 
splenocytes and LN cells, which, respectively, are seeded in the 24-well plate and cultured 
at a concentration of 106 cells/mL at 37°C in a cell incubator with 5% CO
2
.
2. After 24-h incubation, the cells are co-cultured with OVA (10 µg/mL) for further stimula-
tion at a concentration of 106 cells/mL at 37°C in a cell incubator with 5% CO
2
 [25].
3. After 72-h incubation, the cells are washed (105/mL) and stained with fluorescence-labeled 
anti-mouse Abs (1 µg/mL), including CD4, CD8, CD69, H-2Kb-SIINFEKL, CD44 and CD62L 
for labeling T cells, and CD45R (B220), CD80 and IgD for labeling B cells, at 4°C for 1 h.
4. After washing thrice with PBS, the cells are resuspended in 1 mL PBS and assayed by flow 
cytometry to measure the percentages of effector memory T cells (CD44highCD62Llow), cen-
tral memory T cells (CD44highCD62Lhigh), memory B cells (B220+CD80+IgD−), and also the 
Ag-specific CD8+ T cells (CD8+SIINFEKL-MHC-I+) [56].
Also, the supernatants of the splenocytes culture as well as the sera (1:10 dilution) from 
treated mice may be subjected to sandwich ELISA assay of the levels of IFN-γ, granuzyme B, 
IL-4, or other cytokines [25].
4.3.7. Assay of Ag-specific cytotoxicity of CTLs
Production of the Ag-specific cytotoxic T lymphocytes (CTLs) in treated subjects is the 
required immunity induced by a vaccine to erase the intracellular pathogens and is thus a 
desired function of a vaccine that has been purposely designed. The in vivo Ag-specific cytoly-
sis of induced CTLs in the vaccine-treated mice is regarded as the Ag-specific cytotoxicity of 
CTLs and is often analyzed using the CFSE-labeled cells bearing the Ag epitopes [57]. Herein, 
using OVA as the model Ag, the process for assay of the Ag-specific cytotoxicity of CTLs in 
the vaccinated mice is described as follows [24]:
1. Mice are vaccinated twice with an interval of 3 weeks with the OVA-liposomes by the 
desired route.
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2. The syngeneic splenocytes are isolated from naive mice, washed with PBS, and supple-
mented with 3% fetal calf serum (FCS) and 5 mM EDTA at 2 × 107 cells/mL in PBS.
3. The splenocytes are equally divided into two populations, which are incubated with CFSE 
at concentrations of 4 µM (CFSEhigh) and 0.4 µM (CFSElow), respectively, for 5 min at room 
temperature, followed by washing twice with cold PBS.
4. The CFSEhigh splenocytes are pulsed with 1 µM OVA
257–264
 (SIINFEKL) peptide for 1 h at 
37°C in the dark to be target cells identifiable to the OVA-specific CTLs, and then after 
washing thrice with PBS mixed with CFSElow splenocytes as nontarget cells at equal num-
bers (2 × 107 total cells).
5. The mixture of the two splenocyte populations is intravenously injected through tail vein 
into the mice that should have received the second vaccination of OVA-liposomes for 
6 days.
6. After 15 h, the draining nodes and spleen from recipient mice are taken to isolate the cells for 
measuring by flow cytometry the in vivo cytolysis effect of CTLs, which is estimated by the 
loss of the CFSEhigh antigen-pulsed population relative to the control CFSElow population.
4.3.8. Prophylactic efficacy of the Ag-loaded liposomes tested using pathogen challenge
The prophylactic efficacy of liposomal vaccines can be evaluated using the pathogen chal-
lenge experiments using the animals, which should be the hosts that infectious pathogens 
can lodge at and proliferate in. And the animal models fitting host-pathogen interaction 
studies are well summarized in a previous paper [58], and the interested readers can refer 
to the paper for choosing the subjects for carrying out the related research. Notably, the 
pathogen challenge experiments should be conducted in the laboratory with the necessary 
biosafety levels (BSLs) that can absolutely guarantee the full protection of the investigators 
and the complete eradication of the propagation of the pathogens from the laboratory [59]. 
The requirements of BSLs of the laboratories for carrying out pathogen challenge experi-
ments on various types of pathogens with different infection and lethality abilities are rigor-
ously defined in the guideline book of Biosafety in Microbiological and Biomedical Laboratories, 
which can be freely downloaded from the CDC website and should be at hand for every 
researcher who conducts related experiments (https://www.cdc.gov/biosafety/publications/
bmbl5/bmbl.pdf).
To carry out the pathogen challenge experiments, the model animals with the proper age 
are vaccinated once or twice at a proper interval by the aimed administration route with 
the Ag-loaded liposomes at the dose of low, middle and high levels, respectively. And 3 
weeks after the (second) vaccination, the animals are challenged with the pathogen in a 
stock at the challenge dose of 10–50 folds of LD50 (lethal dose 50%) [60]. The animals are 
weighed once and observed twice daily for certain days to observe the protection efficacy, 
and the animals may be euthanized before reaching the moribund state due to humane 
concerns.
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5. Conclusions
Liposomes are widely used as a vehicle for delivering various vaccines due to their numerous 
advantages, including high biocompatibility, diverse and high loading capacity, inherence 
adjuvanticity, relative ease for preparation and for surface decoration to engender a multi-
functional carrier. Particularly, when the liposomes are combined with specific molecules, 
such as ligands to TLRs, the steric stabilization polymers, and the mannosylated compounds, 
the carriers are indeed functioning as a stable and effective vaccine adjuvant-delivery sys-
tem (VADS) to play both the roles of a vaccine adjuvant and a vaccine vehicle. The lipo-
somal VADS can efficiently deliver vaccines to the lymph nodes and even target the APCs 
to elicit robust humoral as well as cellular immunity against the invading pathogens bear-
ing the surface features matching the loaded antigens, as confirmed by the in vitro and in 
vivo experiments, including testing the cellular uptake of liposomes by APCs and the activa-
tion of lymphocytes by liposomes, in vivo tracking of liposomes, assaying secretion of cyto-
kines and immunoglobulins with liposome stimulation, all of which are described with key 
steps and key points in this chapter. As researchers are continuously focusing their research 
interests and efforts on the development of liposomal vaccines, many of the now unknown 
mechanisms underlying the elicited immunity will eventually be brought to light and may 
play a crucial role in rational design of the optimal VADSs. Obviously, various types of the 
liposome-based vaccines may finally be approved by the authorities to enter markets as new 
products against numerous life-threatening diseases, when many advanced platforms are 
managed and set up to further explore and constitute the diverse functional liposomes as an 
effective vaccine adjuvant-delivery system (VADS).
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